The global uveitis treatment market size
is expected to reach USD 765.31 million by 2026. It is projected to register a
CAGR of 5.8% during the forecast period. Rising prevalence of the condition is
anticipated to drive the growth. For instance, according to The Ocular
Immunology and Uveitis Foundation, around 43,000 new eye inflammation cases are
being diagnosed each year in U.S.
Access
Sample Report of this report @ https://www.radiantinsights.com/research/uveitis-treatment-market/request-sample
Eye inflammation is also very prevalent
among children. However, majority of the affected population ranges from 20 to
50 years of age. Growing geriatric population is also an important factor
driving the growth of the market. Rise in number of R&D activities aiming
at new drug development is another attribute increasing the demand for these
treatments.
For instance, ADX-102 Ophthalmic
Solution, by Aldeyra Therapeutics, Inc. is in Phase 2 clinical trial for the
treatment of noninfectious anterior uveitis. The National Eye Institute is also
engaged in conducting and supporting various research studies in this field.
Increasing prevalence of infectious diseases is another contributing factor to
the market growth. Infectious uveitis surrounds a significant array of
potential pathogens, which is likely to pose immense threat to the people
affected.
Further
key findings from the study suggest:
• Corticosteroids led the market in 2018
owing to its wide application for treating noninfectious uveitis as well as
availability of varied corticosteroids drugs
• Monoclonal antibodies are expected to
exhibit lucrative CAGR over the forecast period due to rising development of
novel biologic drugs
• Anterior held the largest market share
in 2018 owing to growing prevalence and tendency of recurrence of anterior
uveitis
• Posterior is anticipated to showcase
lucrative growth over the forecast period owing to rise in the number of
R&D and clinical trials undergoing for the treatment posterior uveitis
• Noninfectious segment held significant
revenue share in 2018 owing to the wide array of treatment methods coupled with
rising cases of the condition
• Infectious segment is gaining traction
in the uveitis treatment market owing to rising prevalence of infectious
diseases
• North America held the largest revenue
share in 2018 owing to increasing prevalence of noninfectious uveitis as well
as rising healthcare expenditure in this region
• Asia Pacific is anticipated to exhibit
lucrative CAGR over the forecast period due to the rising number of infectious
diseases in the developing countries
• Few major companies are Allergan,
Inc.; Valeant Pharmaceutical International, Inc.; Eyegate Pharmaceuticals,
Inc.; AbbVie Inc.; Regeneron Pharmaceuticals, Inc; and Santen Pharmaceutical
Co., Ltd
Continued…
About
Radiant Insights
Radiant Insights is a platform for
companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Media
Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
No comments:
Post a Comment